319 related articles for article (PubMed ID: 14583471)
41. Prointegrin maturation follows rapid trafficking and processing of MT1-MMP in Furin-Negative Colon Carcinoma LoVo Cells.
Deryugina EI; Ratnikov BI; Yu Q; Baciu PC; Rozanov DV; Strongin AY
Traffic; 2004 Aug; 5(8):627-41. PubMed ID: 15260832
[TBL] [Abstract][Full Text] [Related]
42. Red wine polyphenolic compounds strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to thrombin via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth muscle cells.
Oak MH; El Bedoui J; Anglard P; Schini-Kerth VB
Circulation; 2004 Sep; 110(13):1861-7. PubMed ID: 15364805
[TBL] [Abstract][Full Text] [Related]
43. Experimental hindlimb ischemia leads to neutrophil-mediated increases in gastrocnemius MMP-2 and -9 activity: a potential mechanism for ischemia induced MMP activation.
Muhs BE; Gagne P; Plitas G; Shaw JP; Shamamian P
J Surg Res; 2004 Apr; 117(2):249-54. PubMed ID: 15047130
[TBL] [Abstract][Full Text] [Related]
44. Tissue inhibitor of metalloproteinase-2 (TIMP-2) expression during cardiac neural crest cell migration and its role in proMMP-2 activation.
Cantemir V; Cai DH; Reedy MV; Brauer PR
Dev Dyn; 2004 Dec; 231(4):709-19. PubMed ID: 15497141
[TBL] [Abstract][Full Text] [Related]
45. Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor.
Rao CN; Mohanam S; Puppala A; Rao JS
Biochem Biophys Res Commun; 1999 Feb; 255(1):94-8. PubMed ID: 10082661
[TBL] [Abstract][Full Text] [Related]
46. Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis(2-oxopropyl)amine.
Iki K; Tsutsumi M; Kido A; Sakitani H; Takahama M; Yoshimoto M; Motoyama M; Tatsumi K; Tsunoda T; Konishi Y
Carcinogenesis; 1999 Jul; 20(7):1323-9. PubMed ID: 10383907
[TBL] [Abstract][Full Text] [Related]
47. Stepwise activation mechanisms of the precursors of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin).
Nagase H; Suzuki K; Enghild JJ; Salvesen G
Biomed Biochim Acta; 1991; 50(4-6):749-54. PubMed ID: 1666284
[TBL] [Abstract][Full Text] [Related]
48. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13.
Knäuper V; Bailey L; Worley JR; Soloway P; Patterson ML; Murphy G
FEBS Lett; 2002 Dec; 532(1-2):127-30. PubMed ID: 12459476
[TBL] [Abstract][Full Text] [Related]
49. A matrix metalloproteinase expressed on the surface of invasive tumour cells.
Sato H; Takino T; Okada Y; Cao J; Shinagawa A; Yamamoto E; Seiki M
Nature; 1994 Jul; 370(6484):61-5. PubMed ID: 8015608
[TBL] [Abstract][Full Text] [Related]
50. Increased matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase activity and expression in heterotopically transplanted murine tracheas.
Inaki N; Tsunezuka Y; Kawakami K; Sato H; Takino T; Oda M; Watanabe G
J Heart Lung Transplant; 2004 Feb; 23(2):218-27. PubMed ID: 14761770
[TBL] [Abstract][Full Text] [Related]
51. Activation of human progelatinase A/promatrix metalloproteinase 2 by Escherichia coli-derived serine proteinase.
Takeda M; Imada K; Sato T; Ito A
Biochem Biophys Res Commun; 2000 Feb; 268(1):128-32. PubMed ID: 10652225
[TBL] [Abstract][Full Text] [Related]
52. Down-regulation of MT1-MMP expression suppresses tumor cell invasion in metastatic human SW626 ovarian cancer cells.
Wu M; Xu G; Xi L; Wei J; Song A; Han Z; Zhou J; Wang S; Zhu T; Zhang A; Lu Y; Ma D
Oncol Rep; 2006 Feb; 15(2):501-5. PubMed ID: 16391876
[TBL] [Abstract][Full Text] [Related]
53. Cell-based evidence for aminopeptidase N/CD13 inhibitor actinonin targeting of MT1-MMP-mediated proMMP-2 activation.
Sina A; Lord-Dufour S; Annabi B
Cancer Lett; 2009 Jul; 279(2):171-6. PubMed ID: 19264392
[TBL] [Abstract][Full Text] [Related]
54. Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen.
Moilanen M; Sorsa T; Stenman M; Nyberg P; Lindy O; Vesterinen J; Paju A; Konttinen YT; Stenman UH; Salo T
Biochemistry; 2003 May; 42(18):5414-20. PubMed ID: 12731883
[TBL] [Abstract][Full Text] [Related]
55. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase.
Kim YM; Jang JW; Lee OH; Yeon J; Choi EY; Kim KW; Lee ST; Kwon YG
Cancer Res; 2000 Oct; 60(19):5410-3. PubMed ID: 11034081
[TBL] [Abstract][Full Text] [Related]
56. Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP.
Remacle AG; Rozanov DV; Fugere M; Day R; Strongin AY
Oncogene; 2006 Sep; 25(41):5648-55. PubMed ID: 16636666
[TBL] [Abstract][Full Text] [Related]
57. Modulation of matrix gelatinases and metalloproteinase-activating process in acute kidney rejection.
Laplante A; Liu D; Demeule M; Annabi B; Murphy GF; Daloze P; Chen H; Béliveau R
Transpl Int; 2003 Apr; 16(4):262-9. PubMed ID: 12730807
[TBL] [Abstract][Full Text] [Related]
58. Activation of tumor cell matrix metalloproteinase-2 by neutrophil proteinases requires expression of membrane-type 1 matrix metalloproteinase.
Schwartz JD; Shamamian P; Monea S; Whiting D; Marcus SG; Galloway AC; Mignatti P
Surgery; 1998 Aug; 124(2):232-8. PubMed ID: 9706143
[TBL] [Abstract][Full Text] [Related]
59. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity.
Lunter PC; van Kilsdonk JW; van Beek H; Cornelissen IM; Bergers M; Willems PH; van Muijen GN; Swart GW
Cancer Res; 2005 Oct; 65(19):8801-8. PubMed ID: 16204050
[TBL] [Abstract][Full Text] [Related]
60. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer.
Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K
Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
